Active Filter(s):
Details:
Under the terms of the agreement, Hyloris will be responsible for the development, manufacturing, regulatory affairs, and commercialisation of CRD-102. CRD-102 is a novel, patented, extended-release Milrinone capsule.
Lead Product(s): Milrinone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CRD-102
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Hyloris Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $0.1 million
Deal Type: Acquisition October 08, 2021